Angiotensin-neprilysin inhibition in acute decompensated heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema. RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, one-third of patients enrolled did not have a history of HF and just more than half had no previous ACEI or ARB use.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In-hospital initiation of sacubitril-valsartan resulted in a significantly greater proportional reduction in NT-proBNP compared with enalapril at weeks 4 and from baseline (mean time-averaged change in NT-proBNP, −46.7% vs 25.3%).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“This change was consistent across all subgroups, including those without previous HF and those who were RASi-naive.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In the PIONEER-HF study it was noted that in patients admitted with acute decompensated HF and reduced ejection fraction, 65% had a history of HF but only 10% were receiving an MRA at the time of admission.8”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citation
Cited by
Items 801–900 of 999
Karamchand, S., Chipamaunga, T., Naidoo, P., Naidoo, K., Rambiritch, V., Ho, K., CHILTON, R. J., McMahon, K., Leisegang, R. F., Weich, H. S. V. H., et al. (2023) · JMIR Research Protocols · doi:10.2196/44027 · Cited by 2
Comprehensive Unloading Strategy for Rapid Heart Recovery Under Support With Impella
Yamamoto, M., Ishizu, T., Minami, K., Tsuchiya, R., & Hiraya, D. (2023) · Cureus · doi:10.7759/cureus.45590 · Cited by 2
Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment
Wang, C., Fu, G., Wang, X., & Li, N. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2506230 · Cited by 4
Zhang, Z., Chen, S.-J., Xu, X., Luo, G., & Huang, J. (2024) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484241265337 · Cited by 2
Peschanski, N., Zorès, F., Boddaert, J., Douay, B., Delmas, C., Broussier, A., Douillet, D., Berthelot, E., Gilbert, T., Gil‐Jardine, C., et al. (2024) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.09.004 · Cited by 2
Taha, H., Momtaz, M., Elamragy, A. A., Younis, O., & Fahim, M. A. S. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10453-3 · Cited by 3
Uptitration of Sacubitril/Valsartan in Acute Heart Failure: Insight from the PREMIER Study
DOI, S., Tanaka, A., Kida, K., Imai, T., Ueda, Y., NAKANO, Y., Kizaki, Y., Fukuda, D., Matsue, Y., Akashi, Y. J., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.001 · Cited by 2
Park, I. H., Kim, C. H., Jang, W. J., Oh, J. H., Lee, W. S., Yang, J. H., & Gwon, H. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2024.0440 · Cited by 3
Jiang, L., Jing, R., Zhu, Y., Pan, L., Yang, B., Ran, X., Ran, Y., Ding, H., Yang, J., & Wu, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0330038 · Cited by 2
Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Wei, L., He, P., Gao, J., Huang, L., Zhao, L., Zhang, R., Ning, X., & Sun, S. (2025) · Kidney Diseases · doi:10.1159/000548367 · Cited by 2
PANNEFLEK, J., Barbarawi, M., KAKARLAPUDI, Y., Barbarawi, Z., Lauzea, B., & Meraz-Torres, M. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07821-y · Cited by 3
Zonneveld, L. E. E. C., Damman, K., Costanzo, M. R., Voors, A. A., Felker, G. M., & ter Maaten, J. M. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.10.019 · Cited by 2
Marchetti, M., Antiochos, P., Gros, B. P., Abdurashidova, T., Soborun, N., Monney, P. A., Yerly, P., Τζίμας, Γ., Skalidis, I., Vollenweider, P., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.045294 · Cited by 3
Patient-Centered Outcomes in Heart Failure Pharmacotherapy
Kido, K., Hashiguchi, M., & Guglin, M. E. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102356 · Cited by 3
Nguyen, H. T., Thai, T. H., & Pham, H. T. M. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05478-x · Cited by 3
Simultaneous or Sequential Initiation of ARNI and SGLT2I in Patients With HFrEF
Ferreira, J. P., Oliveira, A. S., Saraiva, F. S., Pereira-Sousa, I., Azevedo, R., Angélico‐Gonçalves, A., Grijó, C. M. S. P. M., Santos, M. P., Gavina, C., Santos, M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.070 · Cited by 2
Wang, M., Zuo, Z., Wu, T., & Zhou, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1644757 · Cited by 3
Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure
Angermann, C. E., Gerhardt, T., Blatchford, J., Biegus, J., Collins, S. P., Kosiborod, M., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.102999 · Cited by 4
Jurin, I., Lovrić, D., Gjuras, K., Manola, Š., Hadžibegović, I., Udovičić, M., Rudan, D., Milinković, A., Ćatić, J., Križanović, M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062127 · Cited by 2
Tanaka, A. (2026) · Circulation Journal · doi:10.1253/circj.cj-26-0129 · Cited by 4
Savarese, G., Basile, C., Mebazaa, A., Bayés‐Genís, A., Kang, S., Yoo, B., Eid, C. A., Bozkurt, B., & Butler, J. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag095 · Cited by 3
2025 Clinical practice guidelines for Dilated cardiomyopathy
Chesnikova, A. I., Sitnikova, M. Y., Ageev, F. T., Arutyunov, G. P., Баутин, А. Е., Begrambekova, Y. L., Belenkov, Y. N., Vasyuk, Y. A., Георгиевна, В. Н., Galyavich, A. S., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6672 · Cited by 8
Highlights of AHA Scientific Sessions 2018: a report from the Scientists of Tomorrow
Patel, J., & Smits, A. M. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz005 · Cited by 2
Hoo, Y. Y., Mazlan‐Kepli, W., Hasan, W. N. H. W., Chen, F. J., Devadas, P., Chow, Y. Y., Sow, Q. Y., Azizan, A. A., Malek, A. M. A., Lau, G. S. K., et al. (2021) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1247 · Cited by 3
Park, C. S., Park, J. J., Lee, H., Kang, S., Yoo, B., Jeon, E., Hong, S. K., Shin, J., Kim, M., Park, D.-G., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07238-3 · Cited by 2
A multidisciplinary approach to heart failure care in the hospital: improving the patient journey
Rao, V. U., Bhasin, A., Vargas, J., & Kumar, V. A. (2022) · Hospital Practice · doi:10.1080/21548331.2022.2082776 · Cited by 3
Ozier, D., Rafiq, T., de Souza, R. J., & Singh, S. M. (2022) · CJC Open · doi:10.1016/j.cjco.2022.10.005 · Cited by 2
Renin–Angiotensin–Aldosterone System as an Old New Target in Heart Failure Therapy
Kov́acs, Á., & Barta, J. (2023) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-14952-8_19 · Cited by 2
Matsumura, K., Ijichi, T., Morimoto, J., Takabayashi, K., Miho, M., Ueno, K., Yagi, E., Takase, T., Ueno, M., & Nakazawa, G. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146375 · Cited by 3
Hu, T., Liu, Y., & Lou, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.925375 · Cited by 3
Leong, R. N. F., Trinos, J. P. C. D., Gerodias, F. R., Mojica, V. J. C., Alconera, C. J., Tamayo, R. L. J., Alacapa, J., Almirol, B. J. Q., Paredes, K. P. P., Lim, S., et al. (2023) · Value in Health Regional Issues · doi:10.1016/j.vhri.2023.02.009 · Cited by 2
Schoenborn, E. M., Skersick, P., THRASHER, C., & nd, R. L. P. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2839 · Cited by 2
Pierce, J. B., Blumer, V. L., Choi, S., Hardy, N. C., Greiner, M. A., Carnicelli, A., Shen, X., Lippmann, S., Peterson, P. N., Allen, L. A., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.07.099 · Cited by 2
Braghieri, L., Skoza, W. A., Badwan, O. Z., & Alvarez, P. A. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22095 · Cited by 2
Az új jelszó a csökkent ejekciós frakcióval járó szívelégtelenség bázisterápiájában: ASAP!
Kovács, Á. (2023) · Cardiologia Hungarica · doi:10.26430/chungarica.2023.53.5.502 · Cited by 2
Karaayvaz, E. B., & Güz, G. (2023) · PubMed Central · doi:10.6515/acs.202311_39(6).20230619c · Cited by 2
Heart Failure in CKD Population
Madarasu, R. C., & Marri, H. P. (2024) · Indian Journal of Clinical Cardiology · doi:10.1177/26324636241230375 · Cited by 2
Asano, T., Maeno, Y., Nakano, M., Taguri, M., Miyasaka, M., Nakai, D., Miyazaki, I., Nasu, T., Tanimoto, S., Masuda, N., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102775 · Cited by 2
Full decongestion in acute heart failure therapy
Buttar, C., Alai, H. R., Matanes, F. N., Cassidy, M. M., Stencel, J. D., & Jemtel, T. H. L. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.06.002 · Cited by 4
Voronkov, L. G., Долженко, М. М., Zharinov, O. J., Zaichenko, H. V., Ivanov, D. D., Koval, O., Kravcheniuk, Y. Y., Лашкул, Д. А., Parkhomenko, A. N., Різниченко, А., et al. (2024) · Ukrainian Journal of Cardiology · doi:10.31928/2664-4479-2024.3.5057 · Cited by 4
Levine, A. R., Sasiela, K., & Baker, M. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241262382 · Cited by 2
Advances in understanding and managing pediatric heart failure and transplant
Xu, W., & Richmond, M. E. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001393 · Cited by 2
Huang, Y., Chen, X., Yang, J., Yao, Y., Wang, M., Lu, T., Li, X., Wang, J., Qiao, S., Shi, D., et al. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00670 · Cited by 2
Kim, H. J., Yang, E., Koh, H. B., Jhee, J. H., Park, H. C., & Choi, H. Y. (2024) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.24.021 · Cited by 3
Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction
Zhu, X., Li, X., Zhu, L., Tong, Z., & Xiu-ying, X. (2024) · Cardiovascular Therapeutics · doi:10.1155/2024/6231184 · Cited by 3
Senni, M., Paruchuru, P., Shi, V. C., & Böhm, M. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3634 · Cited by 2
Bakhos, J. J., Saliba, Y., Hajal, J., Achkouty, G., Oskaridjian, H., Albuquerque, M., Azevedo, C., Semaan, A., Suffee, N., Balse, E., et al. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf031 · Cited by 2
Isath, A. M., & Panza, J. A. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.04.001 · Cited by 3
Ráduly, A. P., Edward, K., Balogh, L., Majoros, Z., Pólik, Z., Fülöp, L., Győry, F., Nagy, L., Bódi, B., Kovács, M. B., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082539 · Cited by 3
Heart Failure with Reduced Ejection Fraction
Barkoudah, E., & Yancy, C. W. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.010 · Cited by 2
Advanced cancer therapy: unlocking the potential of small molecule inhibitors
Sen, S., & Karati, D. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2571021 · Cited by 3
Safety and efficacy of sacubitril─valsartan in acute heart failure
Bras, A. L. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0134-5 · Cited by 2
Innovative Strategies in Heart Failure: Present and Future
Rodríguez‐Mañero, M., Grigorian-Shamagian, L., Rábago, G., Abou-Jokh, C., Álvarez, B. Á., Brión, M., & González‐Juanatey, J. R. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2018.12.011 · Cited by 2
The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2020
Martin, A. K., Weiner, M. M., Feinman, J. W., Bhatt, H. V., Fritz, A. V., Townsley, M. M., Sharma, A., Stawiarski, K. M., Patel, S. J., Zhou, E., et al. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.10.031 · Cited by 2
Gerges, F., Komaranchath, A., Al-Bakshy, F., sahli, W. A., & Almaghraby, A. M. (2020) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaa530 · Cited by 2
Adie, S. K., Ketcham, S. W., Abdul-Aziz, A. A., Thomas, M. P., & Konerman, M. C. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001091 · Cited by 2
Efficacy of Sacubitril/Valsartan in the Setting of Acute Heart Failure: A Systematic Review
Mohyeldin, M., Tavares, L. B., Boorenie, M., Abu-Reesh, D., Ejaz, S., Durrani, L., & Khan, S. (2021) · Cureus · doi:10.7759/cureus.18740 · Cited by 3
Habon, T., & Sepp, R. (2022) · Cardiologia Hungarica · doi:10.26430/chungarica.2022.52.2.122 · Cited by 2
Nine contemporary therapeutic directions in heart failure
Almarzooq, Z., Pareek, M., Sinnenberg, L. E., Vaduganathan, M., & Mehra, M. R. (2019) · Heart Asia · doi:10.1136/heartasia-2018-011150 · Cited by 2
Update in recent clinical trials in heart failure
Parikh, V. Y., Bhardwaj, A., Nair, A. P., & Bozkurt, B. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000639 · Cited by 2
Acute Left Heart Failure in the ER
Carlos Jerjes-Sánchez, D., & Vazquez-Guajardo, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-13679-6_13 · Cited by 2
Thornby, K., & Maksutovic, N. M. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020943940 · Cited by 2
Shafrin, J. T., Aliyev, E. R., Brauer, M., Park, S., & Shen, X. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1825454 · Cited by 2
Chen, Y., Guo, L., Zhao, L., Ma, Y., Zhu, X., Xu, Y., & Chen, J. (2020) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2020.12.002 · Cited by 2
Perkembangan Terapi Farmakologis pada Gagal Jantung Akut Dekompensasi
Nursabur, B. M. (2021) · JIMKI Jurnal Ilmiah Mahasiswa Kedokteran Indonesia · doi:10.53366/jimki.v8i3.265 · Cited by 2
Raschi, E., Diemberger, I., Sabatino, M., Poluzzi, E., Ponti, F. D., & Potena, L. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2027909 · Cited by 2
Left Ventricular Output Indices and Sacubitril/Valsartan Titration: Role of Stroke Volume Index
Tolomeo, P., Zucchetti, O., D'Aniello, E., Punzo, N., Marchini, F., Ienno, L. D., Tonet, E., Pavasini, R., Rapezzi, C., Campo, G., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13891 · Cited by 2
Lopatin, Y. M., Arutyunov, G. P., As, A., Ageev, F. T., Antsiferov, M. B., Барбараш, О. Л., Вадимовна, В. С., Георгиевна, В. Н., Galstyan, G. R., Galyavich, A. S., et al. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4945 · Cited by 3
Lou, Q., Li, L., Liu, G., Zhan, C., Zhang, L., Zang, Y., & Li, W. (2022) · BioMed Research International · doi:10.1155/2022/5832543 · Cited by 2
RetractedThe evolving face of heart failure management
Kalsi, M., Dayawansa, N. H., Winderlich, J., & Vaddadi, G. (2022) · Australian Journal of General Practice · doi:10.31128/ajgp-03-22-6350 · Cited by 2
Majoros, Z., Kiss, R. G., & Pál, T. (2022) · Cardiologia Hungarica · doi:10.26430/chungarica.2022.52.2.112 · Cited by 3
Rossini, R., Angelini, F., Giordana, F., COPPINI, L., Ferraro, I., Ruffino, E., Varbella, F., Tizzani, E., Valente, E., & Musumeci, G. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.22.06182-8 · Cited by 2
Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?
Chan, J. C. H., Cowley, E. C., & Chan, M. C. Y. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10030114 · Cited by 3
Ishii, T., Matsue, Y., Matsunaga, Y., Iekushi, K., Homma, Y., & Morita, Y. (2023) · Heart and Vessels · doi:10.1007/s00380-023-02304-2 · Cited by 2
Docherty, K. F., & McMurray, J. J. V. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz223 · Cited by 3
Elshaer, F., Lawand, S. R., Zayed, M., Ayoubi, F. A., Hanfi, Y., & AlQarni, A. A. (2020) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s258978 · Cited by 2
Tópicos Emergentes em Insuficiência Cardíaca: Nova Era do Tratamento Farmacológico
Marcondes‐Braga, F. G., Ramires, F. J. A., Figueiredo, E. L., Figueiredo, J. A., Neto, L. B. D. S., & Rassi, S. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201106 · Cited by 2
Gándara-Ricardo, J. A., Muñoz-Ortiz, E., Aguilar-Molina, O. E., García-Rueda, K. A., Giraldo-Ramírez, S., Salamanca, J. F., & Sénior, J. M. (2021) · Acta Médica Colombiana · doi:10.36104/amc.2021.2108 · Cited by 1
Angelis, G. D. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1598707 · Cited by 2
Kaplinsky, E. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.02.009 · Cited by 2
Angiotensin–Neprilysin Inhibition in de novo Heart Failure – Starting Off Strong
Bhatt, A. S., Vaduganathan, M., & Butler, J. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1675 · Cited by 2
For vaptans, as for life, balance is better
Bhatt, A. S., Yanamandala, M., & Konstam, M. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2042 · Cited by 2
Real-world utilisation of angiotensin-neprilysin inhibitors in older adults with heart failure
Griffin, J. M., & Cheng, R. K.-H. (2021) · Heart · doi:10.1136/heartjnl-2021-319545 · Cited by 2
Corrigendum to: Reduction of hospitalizations for myocardial infarction in Italy in the Covid-19 era
(2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa976 · Cited by 2
Huang, K., Zhang, L., & Zhang, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_1064 · Cited by 2
Time to Reconsider Ejection Fraction in Heart Failure
Seo, Y. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.07.001 · Cited by 2
Sacubitril/Valsartan: Where Mechanism Meets Evidence-Based Medicine
García, S. R., & Garcia, J. A. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3100 · Cited by 3
Barriers to the Implementation of Heart Failure Therapy in the Elderly: Let's Accept the Challenge!
Hoevelmann, J., Volterrani, M., & Emrich, I. E. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3449 · Cited by 2
Сергеевич, Р. А., Ших, Е. В., Kapitonov, K. I., Владимировна, М. М., & Kudryavtsev, A. A. (2021) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn1526 · Cited by 3
Is There Room for Sacubitril-Valsartan in the Treatment of Advanced Heart Failure?
Rohde, L. E. P. (2022) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20220029 · Cited by 1
Evaluating the evidence for sacubitril/valsartan across the continuum of heart failure
Skersick, P., Proco, D., Sharma-Huynh, P., Montepara, C. A., & Rodgers, J. E. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2730 · Cited by 1
Hartnett, S., & Dawn, B. (2023) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-14952-8_20 · Cited by 1
Pandey, A. K., Dhingra, N. K., Pandey, A., Puar, P., Ahmed, S., Verma, R., Mazer, C. D., Butler, J., Badiwala, M. V., Yau, T. M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2825 · Cited by 1
PARASKEVAIDIS, I. A., Xanthopoulos, A. V., Karamichalakis, N., Triposkiadis, F. K., & Tsougos, E. (2023) · Medical Sciences · doi:10.3390/medsci11020038 · Cited by 3
Efficacy of sacubitril / valsartan in the treatment of chronic heart failure: an updated review
Васильевна, Л. М. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-330 · Cited by 1
Hocutt, B., Owen, M. I., & Albert, N. M. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105088 · Cited by 1
Hu, J., Schwann, A. N., Tan, J. W., Nuqali, A., Riello, R. J., & Beasley, M. (2024) · Heart Failure Clinics · doi:10.1016/j.hfc.2024.06.004 · Cited by 2
Shah, K., Mabhugu, S., Obioma, J., Nguyen, Q. P. H., Schillig, J. M., Torres, B. P., Howard, M. L., & Lindley, B. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241282324 · Cited by 1
Shen, Q., Chua, D. C. W., Chan, P. F., Chan, S. W. J., & Wee, H. L. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s502235 · Cited by 1
Reddy, Y., & Pereira, N. L. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.12.005 · Cited by 1
Metadata
- Authors
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 539-548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899841238
- Cited by
- 1,260
- References
- 16
- Citations by year
- 2026: 74 · 2025: 139 · 2024: 136 · 2023: 215 · 2022: 199 · 2021: 189 · 2020: 171 · 2019: 128
- FWCI
- 93.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- acute decompensated heart failure, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, NT-proBNP, renal function, hyperkalemia, angioedema, symptomatic hypotension, drug safety, hospitalization, hemodynamic stabilization, natriuretic peptides
- MeSH terms
- Valsartan, Acute Disease, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiac Output, Low, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Stroke Volume, Tetrazoles, Neprilysin, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.